Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their association with tumor recurrence and resistance to conventional therapies, including radiotherapy a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383520308492 |
| _version_ | 1818648320391774208 |
|---|---|
| author | Javad Masoumi Abdollah Jafarzadeh Jalal Abdolalizadeh Haroon Khan Jeandet Philippe Hamed Mirzaei Hamid Reza Mirzaei |
| author_facet | Javad Masoumi Abdollah Jafarzadeh Jalal Abdolalizadeh Haroon Khan Jeandet Philippe Hamed Mirzaei Hamid Reza Mirzaei |
| author_sort | Javad Masoumi |
| collection | DOAJ |
| description | Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their association with tumor recurrence and resistance to conventional therapies, including radiotherapy and chemotherapy. Chimeric antigen receptor (CAR)-T cells are engineered T cells which express an artificial receptor specific for tumor associated antigens (TAAs) by which they accurately target and kill cancer cells. In recent years, CAR-T cell therapy has shown more efficiency in cancer treatment, particularly regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types makes them as potent tools for CAR-T cell therapy. Here we review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future. Furthermore, we will detail the most important obstacles against CAR-T cell therapy and suggest solutions. |
| first_indexed | 2024-12-17T01:16:33Z |
| format | Article |
| id | doaj.art-925bf26fe44749c3b63acfcb185d95ee |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-17T01:16:33Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-925bf26fe44749c3b63acfcb185d95ee2022-12-21T22:08:58ZengElsevierActa Pharmaceutica Sinica B2211-38352021-07-0111717211739Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospectsJavad Masoumi0Abdollah Jafarzadeh1Jalal Abdolalizadeh2Haroon Khan3Jeandet Philippe4Hamed Mirzaei5Hamid Reza Mirzaei6Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan 77181759111, IranDepartment of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman 7616913555, IranDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranDepartment of Pharmacy, Abdul Wali Khan University, Mardan 23200, PakistanResearch Unit “Induced Resistance and Plant Bioprotection”, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences University of Reims Champagne-Ardenne, BP 1039, 51687, Reims Cedex 2, FranceResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan 8713781147, Iran; Corresponding authors. Tel./fax: +98 31 55540022; Tel./fax: +98 21 66419536.Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran; Corresponding authors. Tel./fax: +98 31 55540022; Tel./fax: +98 21 66419536.Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their association with tumor recurrence and resistance to conventional therapies, including radiotherapy and chemotherapy. Chimeric antigen receptor (CAR)-T cells are engineered T cells which express an artificial receptor specific for tumor associated antigens (TAAs) by which they accurately target and kill cancer cells. In recent years, CAR-T cell therapy has shown more efficiency in cancer treatment, particularly regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types makes them as potent tools for CAR-T cell therapy. Here we review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future. Furthermore, we will detail the most important obstacles against CAR-T cell therapy and suggest solutions.http://www.sciencedirect.com/science/article/pii/S2211383520308492Chimeric antigen receptor T cellCancer stem cellImmunotherapyTumor associated antigensCombination therapyOff-tumor toxicity |
| spellingShingle | Javad Masoumi Abdollah Jafarzadeh Jalal Abdolalizadeh Haroon Khan Jeandet Philippe Hamed Mirzaei Hamid Reza Mirzaei Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects Acta Pharmaceutica Sinica B Chimeric antigen receptor T cell Cancer stem cell Immunotherapy Tumor associated antigens Combination therapy Off-tumor toxicity |
| title | Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects |
| title_full | Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects |
| title_fullStr | Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects |
| title_full_unstemmed | Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects |
| title_short | Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects |
| title_sort | cancer stem cell targeted chimeric antigen receptor car t cell therapy challenges and prospects |
| topic | Chimeric antigen receptor T cell Cancer stem cell Immunotherapy Tumor associated antigens Combination therapy Off-tumor toxicity |
| url | http://www.sciencedirect.com/science/article/pii/S2211383520308492 |
| work_keys_str_mv | AT javadmasoumi cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT abdollahjafarzadeh cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT jalalabdolalizadeh cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT haroonkhan cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT jeandetphilippe cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT hamedmirzaei cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects AT hamidrezamirzaei cancerstemcelltargetedchimericantigenreceptorcartcelltherapychallengesandprospects |